Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16232131 | 1.00 | CHRNA7 (0.42) | CHRNA7TDP1ACHEALOX5MAOA | |
| SCHEMBL16232132 | 1.00 | CHRNA7 (0.42) | CHRNA7TDP1ACHEALOX5MAOA | |
| SCHEMBL3271282 | 0.89 | DPP4 (0.45) | TDP1DPP4ADRB2RECQLKDM4E | |
| SCHEMBL12569051 | 0.86 | ACHE (0.50) | CHRNA7TDP1ACHEALOX5MAOA | |
| SCHEMBL3253749 | 0.86 | ACHE (0.50) | CHRNA7TDP1ACHEALOX5MAOA | |
| SCHEMBL24017147 | 0.86 | ACHE (0.50) | CHRNA7TDP1ACHEALOX5MAOA | |
| SCHEMBL3258924 | 0.86 | ACHE (0.50) | CHRNA7TDP1ACHEALOX5MAOA | |
| SCHEMBL11085901 | 0.84 | CHRNA7 (0.42) | CHRNA7TDP1ACHEALOX5MAOA | |
| Hydrochloric Acid SCHEMBL17137911 | 0.83 | DPP4 (0.48) | CHRNA7TDP1ACHEALOX5MAOA | |
| Hydrochloric Acid SCHEMBL30098282 | 0.83 | DPP4 (0.48) | CHRNA7TDP1ACHEALOX5MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | CHRNA7 190/4885TDP1 1900/4885ACHE 712/4885 |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | CHRNA7 190/4885TDP1 1900/4885ACHE 712/4885 |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | CHRNA7 190/4885TDP1 1900/4885ACHE 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.